These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38888535)

  • 21. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
    Berg DD; Wiviott SD; Scirica BM; Gurmu Y; Mosenzon O; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Johansson PA; Langkilde AM; Raz I; Braunwald E; Sabatine MS
    Circulation; 2019 Nov; 140(19):1569-1577. PubMed ID: 31474116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Morphological characteristics in diabetic cardiomyopathy associated with autophagy.
    Kanamori H; Naruse G; Yoshida A; Minatoguchi S; Watanabe T; Kawaguchi T; Tanaka T; Yamada Y; Takasugi H; Mikami A; Minatoguchi S; Miyazaki T; Okura H
    J Cardiol; 2021 Jan; 77(1):30-40. PubMed ID: 32907780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The limited clinical value of a specific diabetic cardiomyopathy.
    Vigili de Kreutzenberg S; Avogaro A
    Nutr Metab Cardiovasc Dis; 2013 Jul; 23(7):599-605. PubMed ID: 23725770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subclinical Myocardial Impairment in Metabolic Diseases.
    Kosmala W; Sanders P; Marwick TH
    JACC Cardiovasc Imaging; 2017 Jun; 10(6):692-703. PubMed ID: 28595844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EMPA-REG - the "diuretic hypothesis".
    McMurray J
    J Diabetes Complications; 2016; 30(1):3-4. PubMed ID: 26597600
    [No Abstract]   [Full Text] [Related]  

  • 26. Myocardial glucotoxicity: Mechanisms and potential therapeutic targets.
    Battault S; Renguet E; Van Steenbergen A; Horman S; Beauloye C; Bertrand L
    Arch Cardiovasc Dis; 2020 Nov; 113(11):736-748. PubMed ID: 33189592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heart failure in diabetes.
    Jankauskas SS; Kansakar U; Varzideh F; Wilson S; Mone P; Lombardi A; Gambardella J; Santulli G
    Metabolism; 2021 Dec; 125():154910. PubMed ID: 34627874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current landscape of preclinical models of diabetic cardiomyopathy.
    Prakoso D; De Blasio MJ; Tate M; Ritchie RH
    Trends Pharmacol Sci; 2022 Nov; 43(11):940-956. PubMed ID: 35779966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exosomal microRNAs: potential targets for the prevention and treatment of diabetic cardiomyopathy.
    Zhang T; Gao Z; Chen K
    J Cardiol; 2022 Nov; 80(5):423-431. PubMed ID: 35000826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Confirmation of the Cardioprotective Effect of MitoGamide in the Diabetic Heart.
    Park M; Nishimura T; Baeza-Garza CD; Caldwell ST; Pun PBL; Prag HA; Young T; Sauchanka O; Logan A; Forkink M; Gruszczyk AV; Prime TA; Arndt S; Naudi A; Pamplona R; Coughlan MT; Tate M; Ritchie RH; Caicci F; Kaludercic N; Di Lisa F; Smith RAJ; Hartley RC; Murphy MP; Krieg T
    Cardiovasc Drugs Ther; 2020 Dec; 34(6):823-834. PubMed ID: 32979176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stem cells and diabetic cardiomyopathy: from pathology to therapy.
    Liu M; Chen H; Jiang J; Zhang Z; Wang C; Zhang N; Dong L; Hu X; Zhu W; Yu H; Wang J
    Heart Fail Rev; 2016 Nov; 21(6):723-736. PubMed ID: 27221074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors.
    Lahnwong C; Chattipakorn SC; Chattipakorn N
    Cardiovasc Diabetol; 2018 Jul; 17(1):101. PubMed ID: 29991346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy.
    Kim AH; Jang JE; Han J
    Biomed Pharmacother; 2022 Jan; 145():112463. PubMed ID: 34839258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Overview of Diabetic Cardiomyopathy.
    Quaiyoom A; Kumar R
    Curr Diabetes Rev; 2024; 20(5):e121023222139. PubMed ID: 37842898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zinc and cardiovascular disease.
    Little PJ; Bhattacharya R; Moreyra AE; Korichneva IL
    Nutrition; 2010; 26(11-12):1050-7. PubMed ID: 20950764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular mechanisms of diabetic cardiomyopathy.
    Bugger H; Abel ED
    Diabetologia; 2014 Apr; 57(4):660-71. PubMed ID: 24477973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy.
    Januzzi JL; Butler J; Del Prato S; Ezekowitz JA; Ibrahim NE; Lam CSP; Lewis GD; Marwick TH; Perfetti R; Rosenstock J; Solomon SD; Tang WHW; Zannad F
    J Am Coll Cardiol; 2024 Jul; 84(2):137-148. PubMed ID: 38597864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects.
    Sano M; Goto S
    Circulation; 2019 Apr; 139(17):1985-1987. PubMed ID: 31009585
    [No Abstract]   [Full Text] [Related]  

  • 39. The metabolic syndrome in heart failure: insights to specific mechanisms.
    Gargiulo P; Marsico F; Renga F; Dell'Aversana S; Esposito I; Marciano C; Dellegrottaglie S; Perrone-Filardi P; Paolillo S
    Heart Fail Rev; 2020 Jan; 25(1):1-7. PubMed ID: 31414215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reactive oxygen species signalling in the diabetic heart: emerging prospect for therapeutic targeting.
    Wilson AJ; Gill EK; Abudalo RA; Edgar KS; Watson CJ; Grieve DJ
    Heart; 2018 Feb; 104(4):293-299. PubMed ID: 28954833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.